EvanPark
Evan Park is a reporter based in the Bay Area, covering drug pricing and the business of healthcare. He studied statistics at UC Davis and contributes data analysis to Pipeline Briefing's investigations.
Articles by Evan Park
Investigations/September 27
What is OxyContin and why is it at the centre of the opioid crisis?
Drug Pipeline/September 17
Why is the adalimumab market so important?
Investigations/September 4
What is Zolgensma and why is it considered a breakthrough?
Companies/August 30
Why is Novartis considered a controversial drugmaker in the US?
Companies/August 15
Why is Purdue Pharma so controversial?
Companies/August 10
Why is Teva considered a controversial pharmaceutical company?
Investigations/August 5
What did Purdue falsely claim about OxyContin?
Drug Pipeline/July 26
Why did US biosimilars arrive five years after Europe's?
Investigations/July 14
How was Zolgensma's $2.125 million price set?
Companies/July 9